Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:57 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Adalimumab Biosimilar Landscape Report Provides an Analysis of 35+ Companies along with Updated 45+ Marketed and Pipeline Drugs | DelveInsight
January 19, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Adalimumab Biosimilar Landscape Report Provides an Analysis of 35+ Companies along with Updated 45+ Marketed and Pipeline Drugs | DelveInsight ...